OSAKA, Japan and CAMBRIDGE, Massachusetts, June 22, 2024 – Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b,...

− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial − FRUZAQLA (fruquintinib) is the First Novel Targeted Therapy in the EU...

OSAKA, Japan — Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the...

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Dravet Syndrome pipeline constitutes 12+ key companies continuously...

Mezagitamab-Treated Patients Showed Rapid and Sustained Increases in Platelet Counts That Persisted 8 Weeks After the Last Dose Through to Week 161...

LUND, Sweden, June 25, 2024. Camurus today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized,...

These non-invasive, non-pharmacological techniques encompass meditation-based modalities that offer profound benefits increasingly validated by modern...

Three-year-old Drew has a rare condition which causes near-weekly seizures, leaving him unable to walk or speak.

BASKING RIDGE, N.J. & RAHWAY, N.J., June 26, 2024 – The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL)...